Summary of findings 2. Paroxetine compared with agomelatine for depression.
| Paroxetine compared with agomelatine for depression | ||||||
| Patient or population: patients with depression Settings: in‐ and out‐patients Intervention: paroxetine Comparison: agomelatine | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Agomelatine | Paroxetine | |||||
| Failure to respond at endpoint (6‐12 weeks) Follow‐up: 6‐12 weeks | 394 per 1000 | 449 per 1000 (337 to 567) | OR 1.25 (0.78 to 2.01) | 284 (1 study) | ⊕⊕⊕⊝ moderate1 | |
| Failure to respond at 1‐4 weeks | See comment | See comment | Not estimable | 0 (0) | See comment | No trial reported this outcome. |
| Failure to respond at 16‐24 weeks | See comment | See comment | Not estimable | 0 (0) | See comment | No trial reported this outcome. |
| Failure to remit at endpoint HDRS Follow‐up: 6‐12 weeks | 701 per 1000 | 748 per 1000 (637 to 834) | OR 1.27 (0.75 to 2.14) | 284 (1 study) | ⊕⊕⊕⊝ moderate1 | |
| SMD at endpoint HDRS Follow‐up: 6‐12 weeks | The mean SMD at endpoint in the intervention groups was 0.18 standard deviations lower (0.38 lower to 0.02 higher) | 1074 (4 studies) | ⊕⊕⊕⊝ moderate1 | The point estimate of the effect size corresponds to a small effect according to Cohen 1992. | ||
| Failure to complete ‐ any cause ‐ | 234 per 1000 | 232 per 1000 (148 to 343) | OR 0.99 (0.57 to 1.71) | 284 (1 study) | ⊕⊕⊕⊝ moderate1 | |
| Participants with at least some Side Effects | 547 per 1000 | 659 per 1000 (545 to 758) | OR 1.60 (0.99 to 2.59) | 284 (1 study) | ⊕⊕⊕⊝ moderate1 | |
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; SMD: standardized mean difference; OR: Odds ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Blinding stated but not tested. No information on randomisation procedures and allocation concealment.